Search

Your search keyword '"Mosseri, V."' showing total 338 results
Start Over Author "Mosseri, V."
338 results on '"Mosseri, V."'

52. 15 Use of a geriatric assessment questionnaire for older patients in an oncology clinic. Descriptive study of 105 patients at the Institut Curie, a French cancer treatment center

Author

Girre, V., primary, Gridel, G., additional, Mosseri, V., additional, Gisselbrecht, M., additional, Bouleuc, C., additional, Laki, F., additional, Poinsot, R., additional, Ollivier, L., additional, Pierga, J.Y., additional, Diéras, V., additional, and Mignot, L., additional

Published
2006
Full Text
View/download PDF

53. Treatment of high risk medulloblastomas in children above the age of 3 years: A SFOP study

Author

Verlooy, J., primary, Mosseri, V., additional, Bracard, S., additional, Tubiana, A. Lellouch, additional, Kalifa, C., additional, Pichon, F., additional, Frappaz, D., additional, Chastagner, P., additional, Pagnier, A., additional, Bertozzi, A.-I., additional, Gentet, J.C., additional, Sariban, E., additional, Rialland, X., additional, Edan, C., additional, Bours, D., additional, Zerah, M., additional, Le Gales, C., additional, Alapetite, C., additional, and Doz, F., additional

Published
2006
Full Text
View/download PDF

54. Multicentre combined chemotherapy protocol for large cell advanced non hodgkin's lymphoma

Author

Dumont, J., primary, Charpy-Validire, P., additional, Mosseri, V., additional, Gabarre, J., additional, Belanger, C., additional, Turpin, F., additional, Binet, J. L., additional, Dreyfus, F., additional, Fourquet, A., additional, Janvier, M., additional, LeDoussal, M., additional, Missenard, V., additional, Natali, J. C., additional, Raphael, M., additional, Teillet, F., additional, Teillet-Thiebaud, F., additional, Tulliez, M., additional, Varet, B., additional, Vilcoq, J. R., additional, and Asselain, B., additional

Published
2006
Full Text
View/download PDF

55. Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977–1987 and two consecutive French multicenter trials Pegase 02 (1995–96) and Pegase 05 (1997–99)

Author

Palangie, T., primary, Viens, P., additional, Roché, H., additional, Beuzeboc, P., additional, Dieras, V., additional, Dorval, T., additional, Pierga, J.-Y., additional, Mosseri, V., additional, Asselain, B., additional, and Pouillart, P., additional

Published
2004
Full Text
View/download PDF

65. N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma

Author

Doz, F., primary, Peter, M., additional, Schleiermacher, G., additional, Vielh, P., additional, Validire, P., additional, Putterman, M., additional, Blanquet, V., additional, Desjardins, L., additional, Dufier, J.-L., additional, Zucker, J.-M., additional, Mosseri, V., additional, Thomas, G., additional, Magdelénat, H., additional, and Delattre, O., additional

Published
1996
Full Text
View/download PDF

79. Corrélation entre le taux sérique du CD16 soluble et le stade du myélome: étude de 214 sérums

Author

Mathiot, C, primary, Grosbois, B, additional, Teillaud, JL, additional, Tartour, E, additional, Mosseri, V, additional, Euller-Ziegler, L, additional, Daragon, A, additional, Michaux, JL, additional, Facon, T, additional, Bernard, JF, additional, Duclos, B, additional, Laporte, JP, additional, Monconduit, M, additional, and Fridman, WH, additional

Published
1993
Full Text
View/download PDF

87. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

Author

Schleiermacher, G., Michon, J., Huon, I., d'Enghien, C. Dubois, Klijanienko, J., Brisse, H., Ribeiro, A., Mosseri, V., Rubie, H., Munzer, C., Thomas, C., Valteau-Couanet, D., Auvrignon, A., Plantaz, D., Delattre, O., Couturier, J., and Société Française des Cancers de l'Enfant (SFCE)

Subjects
NEUROBLASTOMA, TUMORS in children, GENE expression, CHROMOSOME abnormalities, COMPARATIVE genomic hybridization, PROGNOSIS
Abstract

Whereas neuroblastoma (NB) with MYCN amplification presents a poor prognosis, no single marker allows to reliably predict outcome in tumours without MYCN amplification. We report here an extensive analysis of 147 NB samples at diagnosis, without MYCN amplification, by chromosomal comparative genomic hybridisation (CGH), providing a comprehensive overview of their genomic imbalances. Comparative genomic hybridisation profiles showed gains or losses of entire chromosomes (type 1) in 71 cases, whereas partial chromosome gains or losses (type 2), including gain involving 17q were observed in 68 cases. Atypical profiles were present in eight cases. A type 1 profile was observed more frequently in localised disease (P<0.0001), and in patients of less than 12 months at diagnosis (P<0.0001). A type 2 genomic profile was associated with a higher risk of relapse in the overall population (log-rank test; P<0.0001), but also in the subgroup of patients with localised disease (log-rank test, P=0.007). In multivariate analysis, the genomic profile was the strongest independent prognostic factor. In conclusion, the genomic profile is of prognostic impact in patients without MYCN amplification, making it a help in the management of low-stage NB. Further studies using higher-resolution CGH are needed to better characterise atypical genomic alterations. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

89. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.

Author

Rubie, H., Coze, C., Plantaz, D., Munzer, C., Defachelles, A.S., Bergeron, C., Thomas, C., Chastagner, P., Valteau-Couanet, D., Michon, J., Mosseri, V., Hartmann, O., and Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique

Subjects
NEUROBLASTOMA, DRUG therapy, INFANT disease treatment, THERAPEUTICS, THERAPEUTIC use of antineoplastic agents, SURVIVAL, RESEARCH, ONCOGENES, RESEARCH methodology, CANCER relapse, EVALUATION research, TREATMENT effectiveness, COMPARATIVE studies, CYCLOPHOSPHAMIDE, VINCRISTINE
Abstract

The purpose of this study was to evaluate the efficacy of low-dose chemotherapy in infants with localised and unresectable neuroblastoma (NB). All consecutive infants with localised NB and no N-myc amplification were eligible in the SFOP-NBL 94 study. Primary tumour was deemed as unresectable according to imaging data showing any risk of immediate resection. Diagnostic procedures and staging were conducted according to INSS recommendations. For children, provided that they had no threatening symptom (i.e. vital risk or dumb-bell NB with neurologic deficit), chemotherapy consisted in low-dose cyclophosphamide (5 mg(-1)kg day(-1) x 5 days) and vincristine (0.05 mg kg(-1) at day 1)-CV and repeated one to three times every 2 weeks until surgical excision can be safely performed. No postoperative treatment was given. Between January 1995 and December 1999, 134 consecutive infants with localised NB were registered in the study, of whom 39 had an unresectable NB without N-myc amplification. Among them 28 had no threatening symptom and received CV according to the protocol. Objective response was observed in 14 (50%) and the other 14 were given second-line chemotherapy because of no response. Surgery was attempted in 38 patients including 14 after CV alone, leading to complete resection in 23. Relapses occurred in four patients all local. Survival and event-free survival were 100 and 90+/-5% with a median follow-up of 55 months (range 33-93). In conclusion primary low-dose chemotherapy without anthracyclines is efficient in about half of the infants presenting with an unresectable NB and no N-myc amplification, allowing excellent survival rates without jeopardising their long-term outcome even for nonresponding patients who received standard regimen. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

92. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis.

Author

Chevallier, Bernard, Heintzmann, Francois, Mosseri, Veronique, Dauce, Jean Paul, Bastit, Philippe, Graic, Won, Brunelle, Philippe, Basuyau, Jean Pierre, Comoz, Marc, Asselain, Bernard, Chevallier, B, Heintzmann, F, Mosseri, V, Dauce, J P, Bastit, P, Graic, Y, Brunelle, P, Basuyau, J P, Comoz, M, and Asselain, B

Published
1988
Full Text
View/download PDF

93. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patients.

Author

Doz, François, Khelfaoui, Fatima, Mosseri, Véronique, Validire, Pierre, Quintana, Erica, Michon, Jean, Desjardins, Laurence, Schlienger, Pierre, Neuenschwander, Sylvia, Vielh, Philippe, Putterman, Marc, Dufier, Jean-Louis, Zucker, Jean-Michael, Doz, F, Khelfaoui, F, Mosseri, V, Validire, P, Quintana, E, Michon, J, and Desjardins, L

Published
1994
Full Text
View/download PDF

94. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas.

Author

Tartour, Eric, Gey, Alain, Sastre-Garau, Xavier, Surin, Isabelle Lombard, Mosseri, Veronique, Fridman, Wolf H., Tartour, E, Gey, A, Sastre-Garau, X, Lombard Surin, I, Mosseri, V, and Fridman, W H

Subjects
INTERFERONS, RNA, CANCER patients, RNA analysis, CANCER invasiveness, COMPARATIVE studies, DNA probes, GENES, RESEARCH methodology, MEDICAL cooperation, POLYMERASE chain reaction, PROGNOSIS, RESEARCH, SQUAMOUS cell carcinoma, CERVIX uteri tumors, EVALUATION research, PREDICTIVE tests
Abstract

Background: The production of the cytokine interferon gamma (IFN gamma) by activated peripheral blood mononuclear cells may be reduced in patients with invasive cervical carcinoma. This study was designed to assess the prognostic value of intratumoral IFN gamma messenger RNA (mRNA) levels in such patients.Methods: Biopsy specimens of primary cervical lesions were obtained from 27 patients with invasive squamous cell carcinoma before they received any therapy. Two prognostic groups were considered: 1) a group of 14 patients who had no apparent disease recurrence and who were alive 2 years after diagnosis (good-prognosis group) and 2) a group of 13 patients who had disease recurrence or died during the 2-year follow-up (poor-prognosis group). A competitive reverse transcription-polymerase chain reaction assay was used to measure levels of IFN gamma and beta actin mRNA. The expression of human leukocyte antigen (HLA) class II proteins (which is stimulated by IFN gamma) in tumor cells was studied by immunostaining.Results: Tumor specimens from all 14 patients in the good-prognosis group contained more than 10(3) IFN gamma mRNA copies per 5 x 10(5) beta actin mRNA copies, whereas tumor specimens from only six of the 13 patients in the poor-prognosis group contained this level of IFN gamma mRNA (two-sided P = .006). No clear relationship was observed between levels of IFN gamma mRNA and T-cell or natural killer cell infiltration in tumors; however, a statistically significant association was observed between HLA class II expression on tumor cells and IFN gamma mRNA levels (two-sided P = .01).Conclusions: A subgroup of poor-prognosis cervical carcinoma patients who have low levels of intratumoral IFN gamma mRNA was identified. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

97. N-MYCamplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma

Author

Doz, F., Peter, M., Schleiermacher, G., Vielh, P., Validire, P., Putterman, M., Blanquet, V., Desjardins, L., Dufier, J.-L., Zucker, J.-M., Mosseri, V., Thomas, G., Magdelénat, H., and Delattre, O.

Abstract

Recurrent genetic alterations different from the alteration of the RB1gene on chromosome 13ql4 have been described in retinoblastoma, including structural alterations on the short arm of chromosome 1 and amplification of the N-MYConcogene. These two genetic alterations are major prognostic factors in neuroblastoma, another embryonic neuro-ectodermal tumour. In order to assess the frequency of these alterations and their possible association with clinical parameters in retinoblastoma, we studied a series of 46 retinoblastoma tumour samples. Ploidy was assessed by flow cytometry, N-MYCcopy number was evaluated by a spot-blot procedure using the pNb-1 probe and loss of heterozygosity was investigated by PCR analysis at mini- and microsatellites located on the short arm of chromosome 1. Most tumours were in the diploid or near diploid range; only one case exhibited tetraploidy. N-MYCamplification was observed in only one of the 45 tumours. Loss of heterozygosity on the short arm of chromosome 1 was observed in 9/43 tumours (21%); in particular, its incidence was higher in metastatic than in localised disease (P< 0.05). We suggest that alterations of one or several genes on chromosome 1p might play a role in the oncogenesis or progression of retinoblastoma. Analysis of the long term follow-up of these and additional patients should determine the prognostic value of this parameter.

Published
1996
Full Text
View/download PDF

99. Prospective evaluation of Nmyc amplification and deletion of the short arm of chromosome 1 in neuroblastoma tumours: a single institution study

Author

Michon J, olivier delattre, Jm, Zucker, Peter M, Delonlay P, Luciani S, Mosseri V, Vielh P, Neuenschwander S, and Thomas G

Subjects
Male, Oncogene Protein p55(v-myc), Heterozygote, Gene Amplification, Genes, myc, Infant, DNA, Neoplasm, Polymerase Chain Reaction, Survival Rate, Neuroblastoma, Chromosomes, Human, Pair 1, Humans, Female, Prospective Studies, Chromosome Deletion

Catalog

Books, media, physical & digital resources
See catalog results